Wayne Fenton's impact on industry.
Breier
Alan
A
a.breier@lilly.com
Alphs
Larry
L
Binneman
Brendon
B
D014150:Antipsychotic Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy*; D015195:Drug Design; D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D049674:History, 21st Century; D006801:Humans; D008396:Maryland; D009315:National Institute of Mental Health (U.S.) / Q000266:history; D011570:Psychiatry / Q000266:history; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D014150:Antipsychotic Agents